Anthing is possible my friend, and .10 is definitely possible if Immunotherapy Introducing Revolutionary Nanoparticle Compound LACTOACTIVE iTHER® A potent nanoparticle compound for novel immunotherapy and vaccine development
Across Two Continents Vilacto Bio Inc. conducts in house R&D on critical elements of its drug discovery pipeline, while forming strategic alliances around novel technologies and outsourcing generic research activities to established contract research organizations. Vilacto Bio has operations in New York (USA), Naestved (Denmark) and Lithuania, where the company carries out in-house R&D in wet laboratory facilities. This balance of outsourced and in-house R&D capabilities has enabled Vilacto Bio to maintain high levels of operational efficiency and highly effective use of funds, while ensuring development and operation of key technologies in-house.